Pharmacokinetics of Mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats by بهلولی, شهاب et al.
Received 27 May 2003
Accepted 5 February 2004Copyright # 2004 John Wiley & Sons, Ltd.
BIOPHARMACEUTICS & DRUG DISPOSITION
Biopharm. Drug Dispos. 25: 187–191 (2004)
Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.400
Pharmacokinetics of Mebudipine, a New Calcium
Antagonist, Following Single Intravenous and Oral
Administrations in Rats
Shahab Bohlooli, Fariborz Keyhanfar and Massoud Mahmoudian*
Razi Institute for Drug Research, Iran University of Medical Sciences, P.O. Box 14155-6183, Tehran, Iran
ABSTRACT: The pharmacokinetics of a new calcium antagonist, mebudipine, was studied after a
single intravenous (0.5mg/kg) and oral (10mg/kg) administration to rats. After intravenous
dosing, the plasma concentration of mebudipine declined biexponentially with a terminal half-life
of 2.84 h. The blood clearance was 1.67 l/h/kg and the volume of distribution at steady state was
found to be 6.26 l/kg. After oral dosing (10mg/kg), the Cmax of mebudipine was 25.99.79 ng/ml.
The oral bioavailability was low (5 2%) suggesting a marked first-pass effect. The distribution of
mebudipine into some tissues such as brain, heart, liver and kidney following intravenous
administration (0.5mg/kg) was studied and a rapid distribution of mebudipine into these tissues
was found. It was concluded that brain, heart, liver and kidney are in the same compartment as
plasma (central). Copyright # 2004 John Wiley & Sons, Ltd.
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Introduction
Mebudipine [()-t-butyl, methyl-1, 4-dihydro-2,
6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicar-
boxylate] is a new 1, 4-dihydropyridine deriva-
tive, a calcium channel antagonist developed in
our laboratories [1]. Previous studies have shown
that mebudipine had some advantages over
nifedipine, such as a longer biological half-life,
longer time to reach maximum effect and more
vasoselectivity [1, 2], and shows a higher potency
in inhibiting the calcium evoked spikes in Helix
aspersa [3]. In a previous study, a simple HPLC
method was developed for the assay of mebudi-
pine in plasma and its usefulness in a pharma-
cokinetics study was shown in rabbits after a
single intravenous injection [4]. The plasma
concentration versus time curve of mebudipine
showed a typical two-compartmental decay after
intravenous administration in rabbits [4].
In this paper, the pharmacokinetics of mebu-
dipine was examined in rats after a single
intravenous dose or oral administration using a
previously established chromatographic method.
Materials and Methods
Chemicals
Mebudipine was synthesized in our laboratories
[1]. All other chemicals were of HPLC or
analytical grade.
Animal study
Male Sprague-Dawley rats (20025 g) were
used. They were allowed free access to food
and water during housing, but were fasted
overnight before the study. The drug was
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